Engineered immune cells take aim at Hard-to-Treat lupus

NCT ID NCT06897930

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll 150 adults and first check safety and dosing, then measure how well it controls lupus symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0120 (a dual-target CAR T cell therapy that attacks CD19 and BCMA proteins on immune cells)
What this could lead to: If successful, this could offer a new treatment option for people with severe lupus that hasn't responded to other therapies, potentially reducing disease activity without lifelong medication.
What could go wrong: This is an early-phase trial (1b/2) with only 150 participants, so results may not apply to all lupus patients. CAR T therapy carries risks like cytokine release syndrome and infections, and long-term safety is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
Research Site
NOT_YET_RECRUITING

Stanford, California, 94304-2201, United States
Research Site
SUSPENDED

Tampa, Florida, 33612, United States
Research Site
NOT_YET_RECRUITING

Atlanta, Georgia, 30322, United States
Research Site
NOT_YET_RECRUITING

Chicago, Illinois, 60611, United States
Research Site
NOT_YET_RECRUITING

Baltimore, Maryland, 21287, United States
Research Site
WITHDRAWN

Bethesda, Maryland, 20892, United States
Research Site
RECRUITING

Boston, Massachusetts, 02115, United States
Research Site
RECRUITING

St Louis, Missouri, 63110, United States
Research Site
RECRUITING

New York, New York, 10032, United States
Research Site
RECRUITING

Syracuse, New York, 13202-2240, United States
Research Site
RECRUITING

Chapel Hill, North Carolina, 27599-7280, United States
Research Site
RECRUITING

Charlotte, North Carolina, 28204, United States
Research Site
NOT_YET_RECRUITING

Richmond, Virginia, 23298, United States
Research Site
RECRUITING

Seattle, Washington, 98104, United States
Research Site
RECRUITING

Seattle, Washington, 98195, United States
Research Site
RECRUITING

Darlinghurst, 2010, Australia
Research Site
NOT_YET_RECRUITING

Melbourne, 3000, Australia
Research Site
NOT_YET_RECRUITING

Toronto, M5T 2S8, Canada
Research Site
NOT_YET_RECRUITING

Bristol, BS1 3NU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.